DAPT Study Favored 30 Over 12 Months Of DAPT For Lower Clot And Heart Attack Risk

Share this content:
DAPT study favored 30 over 12 months of DAPT for lower clot and heart attack risk
DAPT study favored 30 over 12 months of DAPT for lower clot and heart attack risk
The Harvard Clinical Research Institute (HCRI) has announced results of the DAPT Study, a major international study that investigated the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following coronary stent implantation.
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




is free, fast, and customized just for you!




Already a member?

Sign In Now »